IG Farben

Agfa Receives Frost & Sullivan 2019 Global New Product Innovation Award for Multi-Purpose Digital Radiography System, DR 800

Retrieved on: 
Monday, February 25, 2019
Agfa, Agfa-Gevaert, IG Farben, Radiography

Frost & Sullivan states that the 3-in-1 DR 800 streamlines imaging workflows while improving productivity and patient care.

Key Points: 
  • Frost & Sullivan states that the 3-in-1 DR 800 streamlines imaging workflows while improving productivity and patient care.
  • Agfa announces today that it has received Frost & Sullivan's 2019 award for New Product Innovation Leader in the Global Multipurpose Digital Radiography Systems Market.
  • Previously, Frost & Sullivan recognized the strong overall performance of Agfa's comprehensive DR portfolio with the North American Product Leadership Award for Digital Radiography, in 2016.
  • Its commitment to technological leadership and customer-driven innovation earn Agfa the 2019 Frost & Sullivan Global New Product Innovation Award."

Target Specialty Products to Be the Exclusive Distributor for New Bayer Product, Imperium

Retrieved on: 
Monday, February 25, 2019
Manufacturing, Chemicals, Plastics, Natural Resources, Agriculture, Companies, IG Farben, Industries, Aspirin, Bayer, Leverkusen, Life sciences, Pest, Target Corporation

Target Specialty Products , a leading provider of Pest and Vector Control and Turf and Ornamental solutions in the U.S. and Canada, will be the exclusive distributor for Imperium a new aerial mosquito-control solution from Bayer.

Key Points: 
  • Target Specialty Products , a leading provider of Pest and Vector Control and Turf and Ornamental solutions in the U.S. and Canada, will be the exclusive distributor for Imperium a new aerial mosquito-control solution from Bayer.
  • We are very excited to offer Imperium through Target Specialty Products, said Dr. Kurt Vandock, Head of Public Health for Bayer.
  • To help deliver this new innovation to the market, Bayer has partnered exclusively with Target Specialty Products to be the sole distributor of Imperium.
  • Target Specialty Products continues to serve the pest, vector, and turf and ornamental management markets from 43 locations across the United States and Canada.

Global Coalescing Agent Market Analysis & Forecast Report 2019-2023 Featuring Key Players - Eastman Chemical, DowDuPont, BASF, Synthomer, and Evonik Industries

Retrieved on: 
Tuesday, February 19, 2019
Business, Chemical industry, BASF, IG Farben, Societates Europaeae, Evonik Industries, Market, Economy of Germany, Economy

Increasing demand from emerging economies, increasing demand for environmentally-friendly coalescent agents, and growing demand for high-performance coatings are creating growth opportunities for the market players.

Key Points: 
  • Increasing demand from emerging economies, increasing demand for environmentally-friendly coalescent agents, and growing demand for high-performance coatings are creating growth opportunities for the market players.
  • However, stringent environmental regulations and the high cost of coalescing agents act as a restraint to the growth of the market.
  • The hydrophilic coalescing agent segment is expected to witness a higher growth rate in the overall coalescing agents market during the forecast period.
  • Some of the key companies profiled in this report are Eastman Chemical Company (US), DowDuPont (US), BASF SE (Germany), Synthomer Plc (UK), and Evonik Industries AG (Germany), among others.

Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)

Retrieved on: 
Friday, February 15, 2019
Industries, Life sciences, Articles, Aspirin, Bayer, IG Farben, Leverkusen, Larotrectinib

As a result of this exercise, the joint co-promotion agreement in the U.S. between Bayer and Loxo Oncology is being converted to full commercialization in the U.S. by Bayer.

Key Points: 
  • As a result of this exercise, the joint co-promotion agreement in the U.S. between Bayer and Loxo Oncology is being converted to full commercialization in the U.S. by Bayer.
  • In November 2017, Bayer and Loxo Oncology entered into a global collaboration for the joint development and commercialization of the TRK inhibitors Vitrakvi and BAY 2731954 (LOXO-195).
  • Following the change of control, Bayer will be solely responsible for the global development and commercialization of both Vitrakvi and BAY 2731954.
  • The oncology franchise at Bayer includes five marketed products and several other compounds in various stages of clinical development.

Moberg Pharma AB Year-end Report 2018

Retrieved on: 
Tuesday, February 12, 2019
Aspirin, Bayer, IG Farben, Leverkusen, Moberg, Companies, Industries, Articles

STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- This year-end report 2018 is made public in advance due to the transaction press release announced earlier today regarding the divestment of Moberg Pharma's OTC-business.

Key Points: 
  • STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- This year-end report 2018 is made public in advance due to the transaction press release announced earlier today regarding the divestment of Moberg Pharma's OTC-business.
  • Moberg Pharma signed an agreement with Mundipharma to commercialize Emtrix in the Middle East and Africa.
  • Moberg Pharma was granted patent in China for MOB-015 until 2032, expanding the global patent scope.
  • Moberg Pharma signed a license agreement with Bayer AG to commercialize MOB-015 in Europe.

Moberg Pharma and Bayer Sign Exclusive License Agreement for MOB-015 in Europe

Retrieved on: 
Monday, February 11, 2019
Companies, Patent law, Aspirin, Bayer, IG Farben, Leverkusen, Terbinafine, Articles, Royalty payment, Moberg, Industries

STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe.

Key Points: 
  • STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe.
  • Under the agreement, Moberg Pharma is eligible to receive up to EUR 50 million contingent on development andcommercial success, as well as supply fees including royalties.
  • Moberg Pharma has entered into a license agreement granting the Consumer Health division of Bayer exclusive European rights to MOB-015, a new topical treatment of onychomycosis based on Moberg's patented proprietary formulation of terbinafine.
  • Bayer will be marketing, distributing and selling MOB-015 in Europe upon completion of Phase III clinical development and registration.

Moberg Pharma and Bayer Sign Exclusive License Agreement for MOB-015 in Europe

Retrieved on: 
Monday, February 11, 2019
Companies, Patent law, Aspirin, Bayer, IG Farben, Leverkusen, Terbinafine, Articles, Royalty payment, Moberg, Industries

STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe.

Key Points: 
  • STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe.
  • Under the agreement, Moberg Pharma is eligible to receive up to EUR 50 million contingent on development andcommercial success, as well as supply fees including royalties.
  • Moberg Pharma has entered into a license agreement granting the Consumer Health division of Bayer exclusive European rights to MOB-015, a new topical treatment of onychomycosis based on Moberg's patented proprietary formulation of terbinafine.
  • Bayer will be marketing, distributing and selling MOB-015 in Europe upon completion of Phase III clinical development and registration.

The global specialty chemical market is anticipated to grow at a CAGR of 5.30% over the forecast period of 2019-2027

Retrieved on: 
Thursday, February 7, 2019
Companies, Industries, Paint manufacturers, IG Farben, Speciality chemicals, Clariant, AkzoNobel, Huntsman Corporation, Fine chemical, Bayer, DuPont, BASF

The global specialty chemical market is anticipated to grow at a CAGR of 5.30% over the forecast period of 2019-2027.

Key Points: 
  • The global specialty chemical market is anticipated to grow at a CAGR of 5.30% over the forecast period of 2019-2027.
  • The market revenue is expected to grow from $XX million in 2018 to $XX million by 2027.
  • The global specialty chemicals market can be divided into four regions.They are North America, Asia-Pacific, Europe and the Rest of World.
  • The major market players in the global specialty chemicals market are PPG Industries Inc., Merck & Co., Inc., Bayer AG, Koninklijke DSM N.V., BASF SE, Huntsman Corporation, Ashland Inc., Clariant SE, Sasol Limited, AkzoNobel N.V., DowDuPont and Solvay S.A.

At HIMSS19, Agfa HealthCare Demonstrates Care You Can See™ With Its Trusted Health IT Ecosystem That Includes Industry Leading EHR, Enterprise Imaging Platform With Embedded AI* and Integrated Care Strategy, to Help Enable Path Towards Precision Health

Retrieved on: 
Tuesday, February 5, 2019
Agfa, Agfa-Gevaert, IG Farben, Companies

Agfa HealthCare provides an innovative response to siloed care systems, creating a scalable ecosystem as providers move from 'intra' to 'interdisciplinary' care delivery.

Key Points: 
  • Agfa HealthCare provides an innovative response to siloed care systems, creating a scalable ecosystem as providers move from 'intra' to 'interdisciplinary' care delivery.
  • Strong and organic growth in Enterprise Imaging, Electronic Health Records and Integrated Care supports the company's goal of guiding its customers around the world to deliver quality care.
  • And with its Integrated Care platform, the company supports care coordination, patient engagement and access to care information, along the care continuum.
  • Agfa HealthCare is a leading provider of diagnostic imaging and healthcare IT solutions for hospitals and care centers around the world.

Connell Bros. Changes Name, Introduces New CEO Role

Retrieved on: 
Friday, February 1, 2019
Companies, IG Farben, Aspirin, Bayer, Leverkusen, Economy of Germany, Industries, Covestro

Owlia's appointment to president and CEO recognizes the strong strategic leadership and direction that she brings to the Company.

Key Points: 
  • Owlia's appointment to president and CEO recognizes the strong strategic leadership and direction that she brings to the Company.
  • She has pushed a company-wide, multiyear effort to build an innovative platform geared towards exceptional customer experience.
  • Prior to joining Connell, Dr. Owlia served as a senior vice president at Bayer MaterialScience, currently known as Covestro.
  • Owlia, based in San Francisco and Hong Kong, joined the Company in 2011 as vice president of North Asia.